Elizabeth J Feuille1, Niloofar Anooshiravani2, Kathleen E Sullivan3, Ramsay L Fuleihan4, Charlotte Cunningham-Rundles2. 1. Weill Cornell Medical College, 505 East 70th street, New York, NY, 10021, USA. ejf9011@med.cornell.edu. 2. Weill Cornell Medical College, 505 East 70th street, New York, NY, 10021, USA. 3. Children's Hospital of Philadelphia, Philadelphia, PA, USA. 4. Children's Memorial Hospital, Chicago, IL, USA.
Abstract
PURPOSE: Autoimmune cytopenia is frequently a presenting manifestation of common variable immune deficiency (CVID). Studies characterizing the CVID phenotype associated with autoimmune cytopenias have mostly been limited to large referral centers. Here, we report prevalence of autoimmune cytopenias in CVID from the USIDNET Registry and compare the demographics and clinical features of patients with and without this complication. METHODS: Investigators obtained demographic, laboratory, and clinical data on CVID patients within the USIDNET Registry. Patients were considered to have autoimmune cytopenia if they had a diagnosis of hemolytic anemia, immune thrombocytopenia (ITP), or autoimmune neutropenia. Baseline characteristics and associated complications of those with autoimmune cytopenia (+AC) and those without (-AC) were compared. RESULTS: Of 990 CVID patients included in the analysis, 10.2% (N = 101) had a diagnosis consistent with autoimmune cytopenia: ITP was diagnosed in 7.4% (N = 73), hemolytic anemia in 4.5% (N = 45), and autoimmune neutropenia in 1% (N = 10). Age at diagnosis, gender, and baseline Ig values did not differ between the +AC and -AC groups. The +AC group was significantly more likely to have one or more other CVID-associated non-infectious complications (OR = 2.9; 95%-CI: 1.9-4.6, P < 0.001), including lymphoproliferation, granulomatous disease, lymphomas, hepatic disease, interstitial lung diseases, enteropathy, and organ-specific autoimmunity. CONCLUSIONS: Autoimmune cytopenias are a common manifestation in CVID and are likely to be associated with other non-infectious CVID-related conditions. In light of prior studies showing increased morbidity and mortality in CVID patients with such complications, a diagnosis of autoimmune cytopenia may have prognostic significance in CVID.
PURPOSE:Autoimmune cytopenia is frequently a presenting manifestation of common variable immune deficiency (CVID). Studies characterizing the CVID phenotype associated with autoimmune cytopenias have mostly been limited to large referral centers. Here, we report prevalence of autoimmune cytopenias in CVID from the USIDNET Registry and compare the demographics and clinical features of patients with and without this complication. METHODS: Investigators obtained demographic, laboratory, and clinical data on CVIDpatients within the USIDNET Registry. Patients were considered to have autoimmune cytopenia if they had a diagnosis of hemolytic anemia, immune thrombocytopenia (ITP), or autoimmune neutropenia. Baseline characteristics and associated complications of those with autoimmune cytopenia (+AC) and those without (-AC) were compared. RESULTS: Of 990 CVIDpatients included in the analysis, 10.2% (N = 101) had a diagnosis consistent with autoimmune cytopenia: ITP was diagnosed in 7.4% (N = 73), hemolytic anemia in 4.5% (N = 45), and autoimmune neutropenia in 1% (N = 10). Age at diagnosis, gender, and baseline Ig values did not differ between the +AC and -AC groups. The +AC group was significantly more likely to have one or more other CVID-associated non-infectious complications (OR = 2.9; 95%-CI: 1.9-4.6, P < 0.001), including lymphoproliferation, granulomatous disease, lymphomas, hepatic disease, interstitial lung diseases, enteropathy, and organ-specific autoimmunity. CONCLUSIONS:Autoimmune cytopenias are a common manifestation in CVID and are likely to be associated with other non-infectious CVID-related conditions. In light of prior studies showing increased morbidity and mortality in CVIDpatients with such complications, a diagnosis of autoimmune cytopenia may have prognostic significance in CVID.
Authors: Francisco A Bonilla; Isil Barlan; Helen Chapel; Beatriz T Costa-Carvalho; Charlotte Cunningham-Rundles; M Teresa de la Morena; Francisco J Espinosa-Rosales; Lennart Hammarström; Shigeaki Nonoyama; Isabella Quinti; John M Routes; Mimi L K Tang; Klaus Warnatz Journal: J Allergy Clin Immunol Pract Date: 2015-11-07
Authors: K Marschall; M Hoernes; M Bitzenhofer-Grüber; P Jandus; A Duppenthaler; W A Wuillemin; J Rischewski; O Boyman; U Heininger; T Hauser; U Steiner; K Posfay-Barbe; J Seebach; M Recher; C Hess; A Helbling; J Reichenbach Journal: Clin Exp Immunol Date: 2015-07-29 Impact factor: 4.330
Authors: Benjamin Gathmann; Nizar Mahlaoui; Laurence Gérard; Eric Oksenhendler; Klaus Warnatz; Ilka Schulze; Gerhard Kindle; Taco W Kuijpers; Rachel T van Beem; David Guzman; Sarita Workman; Pere Soler-Palacín; Javier De Gracia; Torsten Witte; Reinhold E Schmidt; Jiri Litzman; Eva Hlavackova; Vojtech Thon; Michael Borte; Stephan Borte; Dinakantha Kumararatne; Conleth Feighery; Hilary Longhurst; Matthew Helbert; Anna Szaflarska; Anna Sediva; Bernd H Belohradsky; Alison Jones; Ulrich Baumann; Isabelle Meyts; Necil Kutukculer; Per Wågström; Nermeen Mouftah Galal; Joachim Roesler; Evangelia Farmaki; Natalia Zinovieva; Peter Ciznar; Efimia Papadopoulou-Alataki; Kirsten Bienemann; Sirje Velbri; Zoya Panahloo; Bodo Grimbacher Journal: J Allergy Clin Immunol Date: 2014-02-28 Impact factor: 10.793
Authors: Amar Mannina; Jonathan H Chung; Jeffrey J Swigris; Joshua J Solomon; Tristan J Huie; Zulma X Yunt; Tho Q Truong; Kevin K Brown; Rosane Duarte Achcar; Amy L Olson; Christian W Cox; Seth J Kligerman; Douglas Curran-Everett; Evans R Fernández Pérez Journal: Ann Am Thorac Soc Date: 2016-07
Authors: Elizabeth Yakaboski; Ramsay L Fuleihan; Kathleen E Sullivan; Charlotte Cunningham-Rundles; Elizabeth Feuille Journal: J Clin Immunol Date: 2020-03-17 Impact factor: 8.317
Authors: Yasodha Natkunam; Dita Gratzinger; Amy Chadburn; John R Goodlad; John K C Chan; Jonathan Said; Elaine S Jaffe; Daphne de Jong Journal: Blood Date: 2018-08-06 Impact factor: 22.113